SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (2177)12/11/2000 12:15:23 AM
From: scaram(o)ucheRespond to of 4974
 
chalk up another approved biological......

Monday December 11, 12:01 am Eastern Time

Press Release

SOURCE: Elan Corporation plc

FDA Approves Elan's MYOBLOC(TM)

The First Type B Botulinum Toxin Therapy to Be Approved

DUBLIN, Ireland, Dec. 11 /PRNewswire/ -- Elan Corporation, plc
(NYSE: ELN - news; "Elan") announced that the U.S. Food and Drug Administration
("FDA") approved MYOBLOC(TM) (Botulinum Toxin Type B) Injectable Solution. (snip)